ACPE UAN #: 0233-0000-20-013-H04-P
Release Date: October 23, 2020
Expiration Date: October 23, 2023
Activity Type: Knowledge-based
Contact Hours: 1
Activity Fee: Member: $15 Non-Member: $30
Target Audience: Pharmacists who practice in managed care settings.
An estimated 10% of the population has a rare disease, according to the National Organization of Rare Disorders (NORD), which lists over 1,200 rare diseases. While many of these conditions remain without treatment options, therapies that are approved typically come to market through an Accelerated Approval Pathway established by the Food and Drug Administration.
These expedited approval pathways allow patients to access life-altering treatments sooner, but the process can be challenging for formulary decision-makers due to limited evidence and information. In many cases, these drugs are approved with relatively short clinical trials and, for obvious reasons, with very few patients, which makes it difficult to project long-term value and outcomes for patients. One solution for payers has been to utilize the Institute for Clinical and Economic Review’s (ICER) reports to synthesize available clinical information, provide disease background based on specialist consultations and extensive dialogue with patient communities.
This session will cover payer challenges related to the accelerated approval process and how using ICER reports makes clinical evaluations faster and easier. In addition, the session will highlight one payer’s approach to create a process to identify and manage rare disease populations.
At the completion of this activity, participants should be able to:
- Explain why the characteristics of rare disease treatments make them more challenging to manage than treatments for more common conditions.
- Discuss the challenges in obtaining necessary evidence for formulary and utilization management for treatments used to manage rare diseases.
- Describe the Institute for Clinical and Economic Review’s approach to evaluating cures and “short-term transformative” therapies.
- Summarize the strategies for identifying and managing rare disease patient populations within a health plan.
Schedule of Educational Activity:
This activity consists of an audio recording, pre-test assessment questions (not required to pass to continue), post-test questions (required to pass with a score of 70% or higher), and a specific activity evaluation.
The Academy of Managed Care Pharmacy (AMCP) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education
As an accredited provider, AMCP strictly adheres to the ACPE Standards for Commercial Support and other relevant guidelines and standards to ensure the independence of continuing pharmacy education (CPE) activities. AMCP intends that all CPE activities be independent, objective, balanced, evidence-based, and free of any commercial bias.
Participants should claim CPE credit for this home study activity only if they have not claimed credit for the live activity presented at AMCP Nexus 2020 Virtual.
CPE credit will be processed through the AMCP Learn portal and reported directly to CPE Monitor. Please allow 72 hours for processing and posting in your National Association of Boards of Pharmacy (NABP) e-Profile account.
To receive credit for a home study activity you must:
- Review the full content of the home study activity.
- Complete the post-test and achieve a score of 70% or higher.
- Complete a specific activity evaluation.
System Technical Requirements/Viewing Requirements:
Courses and continuing education activities are delivered via your Web browser and Acrobat PDF. For all activities, you should have a basic comfort level using a computer and navigating websites. View the minimum technical and system requirements for all continuing education activities.
|Activity Number||Credit Amount||Accreditation Period|
|ACPE UAN #0233-0000-20-013-H04-P||1 Contact Hour||October 23, 2020 - October 23, 2023|